Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 4, 2010, Pages 1541-1546

  Di, Lie ^a,b   Srivastava, Shekhar ^a,b   Zhdanova, Olga ^a,b   Ding, Yi ^a,b   Li, Zhai ^a,b   Wulff, Heike ^c   Lafaille, Maria ^a,b   Skolnik, Edward Y ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcium signaling; Inflammatory bowel disease; Potassium channels; T helper cells; T cell signaling

Indexed keywords

CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM ION; INTERLEUKIN 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CD4+ T LYMPHOCYTE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH0 CELL; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS;

ANIMALS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, HELPER-INDUCER;

MUS;

EID: 76549083562     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0910133107     Document Type: Article

References (48)

1. Feske S (2007) Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol 7:690-702.
2. Luik RM, Lewis RS (2007) New insights into the molecular mechanisms of store-operated Ca2+ signaling in T cells. Trends Mol Med 13:103-107.
3. Crabtree GR, Olson EN (2002) NFAT signaling: choreographing the social lives of cells. Cell 109 (suppl):S67-S79.
4. Winslow MM, Crabtree GR (2005) Immunology. Decoding calcium signaling. Science 307:56-57.
5. Wulff H, Beeton C, Chandy KG (2003) Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel 6:640-647.
6. Beeton C, Chandy KG (2005) Potassium channels, memory T cells, and multiple sclerosis. Neuroscientist 11:550-562.
7. Beeton C, et al. (2005) Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 67: 1369-1381.
8. Beeton C, et al. (2006) Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 103:17414-17419.
9. Cahalan MD, Wulff H, Chandy KG (2001) Molecular properties and physiological roles of ion channels in the immune system. J Clin Immunol 21:235-252.
10. Ghanshani S, et al. (2000) Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem 275:37137-37149.
11. Liu QH, et al. (2002) Modulation of Kv channel expression and function by TCR and costimulatory signals during peripheral CD4(+) lymphocyte differentiation. J Exp Med 196:897-909.
12. Mosmann TR, Coffman RL (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145-173.
13. Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 383:787-793.
14. Zenewicz LA, Antov A, Flavell RA (2009) CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 15:199-207.
15. Cua DJ, et al. (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421:744-748.
16. Langrish CL, et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233-240.
17. Bettelli E, Korn T, Oukka M, Kuchroo VK (2008) Induction and effector functions of T (H)17 cells. Nature 453:1051-1057.
18. Fanger CM, Neben AL, Cahalan MD (2000) Differential Ca2+ influx, KCa channel activity, and Ca2+ clearance distinguish Th1 and Th2 lymphocytes. J Immunol 164: 1153-1160.
19. Wulff H, et al. (2003) The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest 111:1703-1713.
20. Matheu MP, et al. (2008) Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity 29: 602-614.
21. Begenisich T, et al. (2004) Physiological roles of the intermediate conductance, Ca2+ -activated potassium channel, Kcnn4. J Biol Chem 279:47681-47687.
22. Grgic I, et al. (2009) Disruption of the Gardos channel (KCa3.1) in mice causes subtle erythrocyte macrocytosis and progressive splenomegaly. Pflugers Arch 458:291-302.
23. Wulff H, et al. (2000) Design of a potent and selective inhibitor of the intermediate conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci USA 97:8151-8156.
24. O'Connor W, Jr (2009) A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 10:603-609.
25. Powrie F, et al. (1994) Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1:553-562.
26. Izcue A, et al. (2008) Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 28:559-570.
27. Neurath M, Fuss I, Strober W (2000) TNBS-colitis. Int Rev Immunol 19:51-62.
28. Wulff H, Gutman GA, Cahalan MD, Chandy KG (2001) Delineation of the clotrimazole/ TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1. J Biol Chem 276:32040-32045.
29. Srivastava S, et al. (2006) Histidine phosphorylation of the potassium channel KCa3.1 by nucleoside diphosphate kinase B is required for activation of KCa3.1 and CD4 T cells. Mol Cell 24:665-675.
30. Srivastava S, et al. (2006) Phosphatidylinositol-3 phosphatase myotubularin-related protein 6 negatively regulates CD4 T cells. Mol Cell Biol 26:5595-5602.
31. Srivastava S, et al. (2008) Protein histidine phosphatase 1 negatively regulates CD4 T cells by inhibiting the K+ channel KCa3.1. Proc Natl Acad Sci USA 105:14442-14446.
32. Ito H, Fathman CG (1997) CD45RBhigh CD4+ T cells from IFN-gamma knockout mice do not induce wasting disease. J Autoimmun 10:455-459.
33. Neurath MF, et al. (2002) The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 195:1129-1143.
34. Duerr RH, et al. (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314:1461-1463.
35. Yen D, et al. (2006) IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116:1310-1316.
36. Zhou L, et al. (2007) IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8:967-974.
37. Veldhoen M, Hocking RJ, Flavell RA, Stockinger B (2006) Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol 7:1151-1156.
38. Leppkes M, et al. (2009) RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136:257-267.
39. Awasthi A, Kuchroo VK (2009) IL-17A directly inhibits TH1 cells and thereby suppresses development of intestinal inflammation. Nat Immunol 10:568-570.
40. Fuss IJ, et al. (1996) Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157:1261-1270.
41. Okazawa A, et al. (2002) Th1-mediated intestinal inflammation in Crohn's disease may be induced by activation of lamina propria lymphocytes through synergistic stimulation of interleukin-12 and interleukin-18 without T cell receptor engagement. Am J Gastroenterol 97:3108-3117.
42. Matsuoka K, et al. (2004) T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. Gut 53:1303-1308.
43. Heller F, et al. (2005) Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129:550-564.
44. Sandborn WJ, et al; Ustekinumab Crohn's Disease Study Group (2008) A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135:1130-1141.
45. Ding Y, Shen S, Lino AC, Curotto de Lafaille MA, Lafaille JJ (2008) Beta-catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells. Nat Med 14:162-169.
46. Neurath MF, et al. (1996) Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 183:2605-2616.
47. Toyama K, et al. (2008) The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest 118: 3025-3037.
48. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL (1996) A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 183:2669-2674.